Drugs / TBD09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07525427 | Apr → Nov 2026 expected | pulmonary tuberculosis | Gates Medical Research Institute | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07094932 Comparator | Sep 2025 → Jan 2026 | — | Gates Medical Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBD09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094932 ↗ |
| Route | Oral | “TBD09 will be administered orally” NCT07094932 ↗ |